# Repligen Corporation  Share Price Target ‘$188.07’, now -8.7% Downside Potential

- Link: https://www.directorstalkinterviews.com/repligen-corporation-share-price-target-188.07-now-8.7-downside-potential/4121142712
- Published: 2024-02-16T12:32:50+00:00
- Author: Charlotte Edwards

**Repligen Corporation** with ticker code (RGEN) now have 12 analysts in total covering
the stock. The consensus rating is pointing to ‘buy’. The range between the high
target price and low target price is between $220.00 and $148.00 with the average
share target price sitting at $188.07. (at the time of writing). Now with the previous
closing price of $206.04 this now indicates there is a potential downside of -8.7%.
The 50 day moving average now sits at $181.46 while the 200 day moving average is
$163.50. The market cap for the company is 11.50B. The stock price for the company
is currently $206.03 USD

 The potential market cap would be $10,499,814,775 based on the market consensus.

The company has a dividend yield of 5.38%. Other points of data to note are a P/
E ratio of 101, revenue per share of $12.04 and a 2.08% return on assets.

Repligen Corporation is a life sciences company, which develops and commercializes
bioprocessing technologies and systems that rises flexibility in the process of 
manufacturing biological drugs. The Company’s bioprocessing business consist of 
four franchises, filtration; chromatography; process analytics; and proteins. The
Filtration products are used in process development and process scale production.
The Chromatography franchise includes products used in downstream purification, 
development, and manufacturing of biological drugs. The Process Analytics products
allow end-users to make in-line absorbance measurements allowing for the determination
of protein concentration in filtration, chromatography formulation and fill-finish
applications. The Proteins franchise is represented by its Protein A affinity ligands,
which are a critical component of Protein A chromatography resins used in downstream
purification of virtually all monoclonal antibody (mAb) based drugs on the market.

Share on: